MA45747A - Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines - Google Patents

Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines

Info

Publication number
MA45747A
MA45747A MA045747A MA45747A MA45747A MA 45747 A MA45747 A MA 45747A MA 045747 A MA045747 A MA 045747A MA 45747 A MA45747 A MA 45747A MA 45747 A MA45747 A MA 45747A
Authority
MA
Morocco
Prior art keywords
cells
generation
souh
human pluripotent
functional beta
Prior art date
Application number
MA045747A
Other languages
English (en)
Inventor
Nicolaj Strøyer Christophersen
Ulrik Døhn
Mattias Hansson
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA45747A publication Critical patent/MA45747A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/845—Gamma amino butyric acid [GABA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne la génération de cellules bêta fonctionnelles à partir de progéniteurs endocriniens dérivés de cellules souches pluripotentes humaines. La présente invention concerne également des cellules bêta fonctionnelles produites par lesdits procédés et utilisations de ces cellules bêta.
MA045747A 2016-02-24 2017-02-24 Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines MA45747A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16157181 2016-02-24

Publications (1)

Publication Number Publication Date
MA45747A true MA45747A (fr) 2019-01-02

Family

ID=55588039

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045747A MA45747A (fr) 2016-02-24 2017-02-24 Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines

Country Status (7)

Country Link
US (1) US11274280B2 (fr)
EP (1) EP3420073B1 (fr)
JP (1) JP7123802B2 (fr)
CN (1) CN108699515A (fr)
ES (1) ES2967942T3 (fr)
MA (1) MA45747A (fr)
WO (1) WO2017144695A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
KR102232650B1 (ko) 2013-06-11 2021-03-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
EP3954759A1 (fr) 2014-05-16 2022-02-16 Janssen Biotech, Inc. Utilisation de petites molécules pour améliorer l'expression mafa dans des cellules endocrines pancréatiques
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
MA45502A (fr) * 2016-06-21 2019-04-24 Janssen Biotech Inc Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases
US20200199540A1 (en) 2017-09-11 2020-06-25 Novo Nordisk A/S Enrichment of nkx6.1 and c-peptide co-expressing cells derived in vitro from stem cells
AU2018370029B2 (en) 2017-11-15 2024-11-07 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
IL277025B2 (en) * 2018-03-02 2024-04-01 Vertex Pharma Methods of enhancing stem cell differentiation into beta cells
WO2020033879A1 (fr) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Différenciation d'ilot dérivé de cellules souches
AU2018439389A1 (en) * 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
EP3953451A1 (fr) 2019-04-08 2022-02-16 Novo Nordisk A/S Production d'endoderme pancréatique à partir d'endoderme définitif dérivé de cellules souches
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
WO2021099532A1 (fr) 2019-11-22 2021-05-27 Novo Nordisk A/S Microsphères neuronales regroupée par rotation et application associée
US20240226179A1 (en) * 2020-02-28 2024-07-11 The Trustees Of The University Of Pennsylvania Tissue culture media for survival and engraftment of human pancreatic islets
JP2023516672A (ja) 2020-03-02 2023-04-20 ノヴォ ノルディスク アー／エス 汚染性残留未分化多能性幹細胞を検出するための多能性マーカーの使用
CN116018150A (zh) 2020-08-28 2023-04-25 诺和诺德股份有限公司 用于筛选干细胞衍生的β样细胞的体外群体的方法及其新型标志物
TW202242095A (zh) 2020-12-18 2022-11-01 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
WO2022136215A1 (fr) 2020-12-21 2022-06-30 Novo Nordisk A/S Cellules immuno-furtives sûres
CN113069440A (zh) * 2021-04-08 2021-07-06 澳门大学 甲状腺素的新的应用、培养多能干细胞的方法和培养基
WO2023076554A1 (fr) * 2021-10-28 2023-05-04 Memorial Sloan-Kettering Cancer Center COMPOSITIONS ET PROCÉDÉS POUR FAVORISER LA MATURATION DE CELLULES IN VITRO<i />
WO2023118050A1 (fr) 2021-12-21 2023-06-29 Novo Nordisk A/S Utilisation de nouveaux marqueurs pour détecter des cellules souches pluripotentes
WO2024151541A1 (fr) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Souris auto-immune présentant un diabète de type 1
WO2024243236A2 (fr) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Procédés d'administration de cellules des îlots pancréatiques et procédés associés
WO2025093467A1 (fr) 2023-10-31 2025-05-08 Novo Nordisk A/S Procédés pour empêcher l'apparition de cellules indésirables pendant la différenciation de cellules souches pluripotentes humaines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784415C (fr) 2009-12-23 2019-06-18 Jean Xu Differenciation de cellules souches embryonnaires humaines
US9752125B2 (en) 2010-05-12 2017-09-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2723852B1 (fr) 2011-06-21 2021-11-17 Novo Nordisk A/S Induction efficace d'endoderme définitif à partir de cellules hes
IN2014DN10053A (fr) 2012-04-30 2015-08-14 Univ Health Network
US20150247123A1 (en) 2012-09-03 2015-09-03 Novo Nordisk A/S Generation of pancreatic endoderm from Pluripotent Stem cells using small molecules
WO2014048788A1 (fr) 2012-09-27 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour la production d'une population de cellules bêta pancréatiques
WO2014105546A1 (fr) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines en cellules endocrines pancréatiques au moyen de régulateurs de hb9
WO2014127219A1 (fr) 2013-02-14 2014-08-21 The Cleveland Clinic Foundation Méthodes destinées à induire des destins cellulaires à partir de cellules pluripotentes
JP2016521971A (ja) 2013-04-23 2016-07-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法１１９条第（ｅ）項に基づき、２０１４年１月２９日出願の米国特許仮出願第６１／９３２，９３５号、２０１３年９月１７日出願の米国特許仮出願第６１／８７８，７６９号、および２０１３年４月２３日出願の米国特許仮出願第６１／８１４，９２０号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、ＹａｑｕｂＨＡＮＮＡ、ＮｏａＮＯＶＥＲＳＨＴＥＲＮ、およびＹｏａｃｈＲＡＩＳによる米国特許出願（発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法（ＩＳＯＬＡＴＥＤＮＡＩＶＥＰＬＵＲＩＰＯＴＥＮＴＳＴＥＭＣＥＬＬＳＡＮＤＭＥＴＨＯＤＳＯＦＧＥＮＥＲＡＴＩＮＧＳＡＭＥ）」）（代理人事件記録簿第５８８７０号）にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。
US9540613B2 (en) 2013-04-29 2017-01-10 Wisconsin Alumni Research Foundation Methods for producing insulin-secreting beta cells from human pluripotent stem cells
KR102232650B1 (ko) 2013-06-11 2021-03-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
WO2015028614A1 (fr) * 2013-08-30 2015-03-05 Novo Nordisk A/S Génération de cellules progénitrices endocrines à partir de cellules souches pluripotentes humaines à l'aide de petites molécules
US20150250824A1 (en) * 2014-03-07 2015-09-10 The Research Foundation For The State University Of New York Methods and compositions for expansion of stem cells and other cells
EP3954759A1 (fr) 2014-05-16 2022-02-16 Janssen Biotech, Inc. Utilisation de petites molécules pour améliorer l'expression mafa dans des cellules endocrines pancréatiques
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
AU2018439389A1 (en) 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors

Also Published As

Publication number Publication date
WO2017144695A9 (fr) 2017-10-19
JP7123802B2 (ja) 2022-08-23
EP3420073C0 (fr) 2023-11-08
US20190085295A1 (en) 2019-03-21
WO2017144695A1 (fr) 2017-08-31
EP3420073A1 (fr) 2019-01-02
JP2019510482A (ja) 2019-04-18
EP3420073B1 (fr) 2023-11-08
US11274280B2 (en) 2022-03-15
ES2967942T3 (es) 2024-05-06
CN108699515A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
MA45747A (fr) Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CL2018001223A1 (es) Locus óptimo de la soja (divisional de solicitud 201601063)
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MX394516B (es) Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MA43018B1 (fr) Anticorps anti-pd1 et procédés d&#39;utilisation
MA40671B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
ECSP13012877A (es) FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX390083B (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
MA51107A (fr) Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
EA201991798A1 (ru) Стабильные при хранении составы
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
MX2021000066A (es) Métodos y composiciones para la preparacion de tagatosa a partir de fructosa.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
BR112022001207A2 (pt) Método de obtenção de mitocôndrias de células e mitocôndrias obtidas
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2019015868A (es) Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima.
BR112019021300A8 (pt) Composições de fragrâncias e produtos com efeitos de melhora do humor